Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab for Post-Traumatic Headache
NCT03347188Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2017
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of fremanezumab in post-traumatic headache (PTH), sponsored by Teva Pharmaceutical Industries Ltd.. Started Dec 2017; status: completed.
02
Drugs
fremanezumab
03
Conditions
post-traumatic headache (PTH)
Beyond the preview
Go deeper on NCT03347188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347188.